Explore 3 Stock Ideas & Industry Insights Download Free Report

8082-737-676
Shopping Cart 0
countryflagUK
Login

BioAge Labs, Inc

Healthcare US BIOA

15.7USD
-1.32(7.76%)

Last update at 2026-06-05T20:00:00Z

Day Range

15.6817.16
LowHigh

52 Week Range

3.6724.00
LowHigh

Fundamentals

  • Previous Close 17.02
  • Market Cap834.34M
  • Volume375918
  • P/E Ratio-
  • Dividend Yield-%
  • EBITDA-92.56700M
  • Revenue TTM8.99M
  • Revenue Per Share TTM0.25
  • Gross Profit TTM -64.97100M
  • Diluted EPS TTM-2.24

Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website

Analyst Recommendations

Financials

Income Statement

Balance Sheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2017-12-31
Type yearly yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2017-12-31
Income before tax -80.60500M -71.10900M -63.85400M -39.72200M -102.10504M
Minority interest - - - - -
Net income -80.60500M -71.10900M -63.85400M -39.72200M -98.15147M
Selling general administrative 27.81M 19.16M 14.51M 9.45M 10.41M
Selling and marketing expenses - - - - 1.94M
Gross profit 8.99M - - - -7.38050M
Reconciled depreciation 0.21M 0.17M 0.16M 0.13M -
Ebit -92.99300M -68.74200M -45.96900M -39.50400M -98.06974M
Ebitda -92.78000M -68.57500M -45.80700M -39.37500M -88.72361M
Depreciation and amortization 0.21M 0.17M 0.16M 0.13M 9.35M
Non operating income net other - - - - -
Operating income -92.78000M -78.19400M -48.40000M -39.96900M -110.01330M
Other operating expenses 101.78M 78.19M 48.40M 39.97M 124.96M
Interest expense 0.70M 2.37M 7.79M 0.24M -
Tax provision - - - - -
Interest income 13.09M 9.63M 2.43M 0.47M -
Net interest income 12.39M 7.26M -5.36300M 0.22M -
Extraordinary items - - - - -
Non recurring - - - - -
Other items - - - - -
Income tax expense - -71.10900M 7.79M 0.24M 0.08M
Total revenue 8.99M 0.00000M 0.00000M 0.00000M 14.94M
Total operating expenses 101.78M 78.19M 48.40M 39.97M 102.63M
Cost of revenue 0.21M - - - 22.32M
Total other income expense net 12.18M 7.08M -15.45400M 0.25M 7.91M
Discontinued operations - - - - -
Net income from continuing ops -80.60500M -71.10900M -63.85400M -39.72200M -
Net income applicable to common shares - - - - -
Preferred stock and other adjustments - - - - -
Breakdown 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2017-12-31
Type yearly yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2017-12-31
Total assets 294.89M 358.23M 25.92M 28.43M 69.51M
Intangible assets - - - - 4.04M
Earning assets - - - - -
Other current assets 4.93M 2.75M 3.66M 0.39M 0.93M
Total liab 22.84M 35.11M 199.32M 140.99M 47.66M
Total stockholder equity 272.05M 323.13M -173.39600M -112.55900M 21.85M
Deferred long term liab - - - - -
Other current liab 8.48M 11.75M 7.94M 3.38M -6.15342M
Common stock - - - - 0.52M
Capital stock 0.00000M 0.00000M 0.00000M 0.00000M -
Retained earnings -333.41600M -252.81100M -181.70200M -117.84800M -318.91945M
Other liab - - - - -
Good will - - - - -
Other assets - - - - -
Cash 188.89M 354.35M 21.64M 27.64M 4.63M
Cash and equivalents - - - - -
Total current liabilities 20.14M 27.77M 58.17M 5.86M 11.30M
Current deferred revenue 5.75M 7.83M 3.31M 3.36M -
Net debt -183.32800M -345.64500M 31.61M -25.17600M 32.98M
Short term debt 3.23M 6.20M 45.05M 0.22M 4.92M
Short long term debt 2.65M 6.00M 44.86M 0.17M -
Short long term debt total 5.56M 8.70M 53.25M 2.47M 37.62M
Other stockholder equity 605.19M 575.69M 8.14M 5.12M 352.81M
Property plant equipment - - - - -
Total current assets 286.79M 357.10M 25.31M 28.03M 15.25M
Long term investments 4.13M 0.10M 0.10M 0.00000M -
Net tangible assets - - - - -
Short term investments 92.21M 0.00000M - - -
Net receivables 0.77M 0.00000M - - 4.86M
Long term debt - 2.50M 8.20M 2.25M -
Inventory - - - - 4.82M
Accounts payable 2.67M 2.00M 1.87M 2.26M 6.15M
Total permanent equity - - - - -
Noncontrolling interest in consolidated entity - - - - -
Temporary equity redeemable noncontrolling interests - - - - -
Accumulated other comprehensive income 0.28M 0.24M 0.16M 0.17M -12.55931M
Additional paid in capital - - - - -
Common stock total equity - - - - -
Preferred stock total equity - - - - -
Retained earnings total equity - - - - -
Treasury stock - - - - -
Accumulated amortization - - - - -
Non currrent assets other 4.25M 0.24M - 0.03M 0.77M
Deferred long term asset charges - - - - -
Non current assets total 8.10M 1.13M 0.62M 0.40M 54.27M
Capital lease obligations 2.91M 0.20M 0.19M 0.05M -
Long term debt total - - - - -
Breakdown 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2017-12-31
Type yearly yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2017-12-31
Investments -94.49700M -0.36600M -0.26600M -0.10300M -
Change to liabilities - - - - -
Total cashflows from investing activities -95.21600M -0.36600M - - -
Net borrowings -6.00000M -6.00000M - - -
Total cash from financing activities 11.47M 381.20M 34.94M 2.50M 18.85M
Change to operating activities - - - - -
Net income -80.60500M -71.10900M -63.85400M -39.72200M -98.15147M
Change in cash -165.46100M 329.39M -2.68700M -33.53900M -11.52835M
Begin period cash flow 354.35M 24.96M 27.64M 61.18M 16.16M
End period cash flow 188.89M 354.35M 24.96M 27.64M 4.63M
Total cash from operating activities -81.62700M -51.52200M -37.36200M -36.18100M -29.78908M
Issuance of capital stock 17.16M 391.62M - - -
Depreciation 0.21M 0.17M 0.16M 0.13M 9.35M
Other cashflows from investing activities - - - - -
Dividends paid - - - - -
Change to inventory - - - - 0.03M
Change to account receivables -0.76900M 0.00000M - - -3.67459M
Sale purchase of stock - - - - -4.63167M
Other cashflows from financing activities - 165.58M -0.05900M -0.00100M 18.85M
Change to netincome - - - - -
Capital expenditures 0.72M 0.37M 0.17M 0.10M 0.00000M
Change receivables - - - - -
Cash flows other operating - - - - -
Exchange rate changes - - - - -
Cash and cash equivalents changes - - - - -
Change in working capital -11.82800M 11.18M 6.71M 0.80M 17.84M
Stock based compensation 11.69M 6.98M 3.02M 2.54M 5.18M
Other non cash items -1.09800M 1.26M 16.60M 0.10M 36.00M
Free cash flow -82.34600M -51.88800M -37.52800M -36.28400M -29.78908M

Peer Comparison

Sector: Healthcare Industry: Drug Manufacturers - Specialty & Generic

Company Change (USD) Price (USD) Trailing PE (x) Forward PE (x) Price Sales TTM (x) Price to Book Value (x) Enterprise Value to Revenue (x)
BIOA
BioAge Labs, Inc		 -1.32 7.76% 15.70 - - 92.76 3.02 60.59
ZTS
Zoetis Inc		 -0.08 0.10% 79.44 40.18 30.96 10.67 17.60 11.27 26.18
MKKGY
Merck KGaA ADR		 -1.13 3.48% 31.32 21.25 14.93 3.10 2.14 3.60 12.98
MKGAF
MERCK Kommanditgesellschaft auf Aktien		 -5.4 3.30% 158.31 21.73 14.95 3.16 2.15 3.56 12.82
GALDY
GALDERMA GROUP AG		 -0.13 0.32% 40.45 74.21 41.67 8.64 5.55 9.15 42.22

Reports Covered

Stock Research & News

View All

Profile

BioAge Labs, Inc., a clinical-stage biopharmaceutical company, develops therapeutic product candidates for metabolic diseases. The company's technology platform and differentiated human datasets that allows users to identify targets based on insights into molecular changes that drive aging. Its lead product candidate includes BGE-102, an orally available brain-penetrant small-molecule NLRP3 inhibitor which is in Phase 1 clinical trail for the treatment of atherosclerotic cardiovascular disease, as well as for the treatment of diabetic macular edema and geographic atrophy; and develops APJ agonists for obesity, including programs targeting both oral and parenteral administration. The company has collaboration agreement with Novartis Pharma AG to identify and validate novel therapeutic drug targets by investigating the biological mechanisms that drive diseases related to aging and mediate. BioAge Labs, Inc. was incorporated in 2015 and is headquartered in Emeryville, California.

BioAge Labs, Inc

5885 Hollis Street, Emeryville, CA, United States, 94608

Key Executives

Name Title Year Born
Dr. Kristen Fortney Ph.D. Co-Founder, CEO, President, Treasurer, Secretary & Director 1983
Mr. Eric Morgen M.D. Co-Founder, COO & Director 1982
Dr. Paul D. Rubin M.D. Chief Medical Officer & Executive VP of Research 1954
Dr. Dov A. Goldstein M.B.A., M.D. Chief Financial Officer 1967
Mr. Ralph Scarborough Vice President of Finance & Accounting NA
Mr. Rusty Montgomery Ph.D. Senior Vice President of Research NA
Ms. Julie Gammelgard Senior Vice President of People NA
Dr. Peng Leong M.B.A., Ph.D. Chief Business Officer & Therapeutic Area Head of Brain Aging NA
Dr. Carrie-Lynn Langlais Furr Senior Vice President of Regulatory Affairs NA
Mr. Justin Rebo Senior Vice President of Translational Aging Biology NA

Disclaimer - This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.

We use cookies to help us improve, promote, and protect our services. By continuing to use this site, we assume you consent to our Cookies Policy. For more information, read our Privacy Policy and Terms and Conditions